Overview

A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

Status:
Completed
Trial end date:
2017-02-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the serum testosterone levels in patients with Metastatic Castration-Resistant Prostate Cancer on SoluMatrix™ Abiraterone Acetate as Compared to Abiraterone Acetate
Phase:
Phase 2
Details
Lead Sponsor:
Churchill Pharmaceutical LLC
Sun Pharma Global FZE
Treatments:
Abiraterone Acetate
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate